

## Acute Ophthalmoplegia without Ataxia: A Case Report

Edvard Ehler<sup>1,2</sup>, Leona Formanova<sup>1,2</sup>, Alena Melekova<sup>1,2</sup>, Petra Mandysova<sup>1,2</sup> and Martin Valis<sup>3\*</sup>

<sup>1</sup>Department of Neurology, Pardubice Regional Hospital, Pardubice, Czech Republic

<sup>2</sup>Faculty of Health Studies, University of Pardubice, Pardubice, Czech Republic

<sup>3</sup>Department of Neurology, Charles University and University Hospital, Hradec Kralove, Czech Republic

**Corresponding author:** Martin Valis, Department of Neurology, Charles University and University Hospital, Sokolska 581, 500 05, Hradec Kralove, Czech Republic, Tel: +420 495 835 233; Fax: +420 495 835 200; E-mail: valismar@seznam.cz

**Rec date:** Mar 27, 2016; **Acc date:** May 13, 2016; **Pub date:** May 16, 2016

**Copyright:** © 2016 Ehler E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

**Background:** Miller Fisher syndrome is a well-known disorder that belongs to a group of conditions with a high level of antibodies against ganglioside GQ1b. It is characterized by acute onset of ataxia, areflexia, and ophthalmoplegia. In cases of acute-onset ophthalmoplegia without ataxia, the diagnosis is more difficult; therefore, it is frequently delayed.

**Case Report:** We report one such case of rapid onset of internal ophthalmoplegia, followed by external ophthalmoplegia. The diagnostic process was challenging, but eventually, a high level of antibodies against GQ1b confirmed the diagnosis. Because the clinical and electrophysiological findings were limited only to the presence of anti-GQ1b antibodies, a combination with a generalized form of Guillain-Barre syndrome could be excluded.

**Conclusion:** Consequently, the patient was not treated with immunotherapy. At 4 months, the patient had made a good recovery.

**Keywords:** Miller Fisher syndrome; Antibodies against GQ1b; Ophthalmoplegia; Immunotherapy

### Introduction

Ophthalmoplegia without ataxia, areflexia, or both has been designated as atypical Miller Fisher syndrome or acute ophthalmoplegia (AO) [1]. In such patients, the determination of the presence of serum antibodies against ganglioside GQ1b is useful for confirming the diagnosis [2]. Approximately 5% of North American and European patients with Guillain-Barre syndrome (GBS) have Fisher syndrome (FS), whereas in Eastern Asia, the proportion of patients with FS is 25–30% [3]. Most cases of FS are characterized by external ophthalmoplegia. However, in a fairly large group of patients with antibodies against GQ1b internal ophthalmoplegia was found in 163 (35%) patients in the FS subgroup [4].

A patient presented to our hospital with acute onset of bilateral internal and external ophthalmoplegia, without ataxia or pain. Finally, high titers of antibodies against GQ1b provided confirmation of correct diagnosis. The purpose of this report is to describe the case.

### Case Report

In the second half of January 2015, a previously healthy 41-year-old male IT specialist developed a viral infection that was manifested by cough and throat pain. Three weeks later he developed eye fatigue, followed by blurred vision, and on the third day, by diplopia. Nine days later, he was admitted to our neurology department, with diplopia and mydriasis that was not reactive to light. Moreover, he made no attempt at eye convergence. He had limited movement of the eyeballs to the sides, more so to the left, and his left eye exhibited slight limitation of

vertical movement. Downward gaze was within normal limits; however, he could not converge his eyes (Figures 1 and 2). The remainder of the patient's neurological examination, including the mimic and skeletal muscles, was normal.



**Figure 1:** Mydriasis on both eyes with divergent strabismus and a mild upper lid ptosis right.



**Figure 2:** Upward look with mydriasis more on the left eye, restriction of upward movement with manifestation of divergency of eyeballs.

The patient's laboratory findings were within normal limits, except for an elevated level of cholesterol (5.98 mmol/l) and serum anti-GQ1b

413 units (normal value <10). All other values of anti-ganglioside antibodies in the blood were within the normal range (anti-asialo-GM1: 13.1; anti-GM1: 16.1; anti-GM2: 0.1; anti-GD1a: 6.4; anti-GD1b: 5.9). Until we obtained the results of the antibody levels against gangliosides, we had tested the patient based on his eye movement disorder. Magnetic resonance imaging (MRI) of the brain, orbits, and the cervical spinal cord, enhanced with gadolinium, showed no abnormality. MRI angiography of intracranial and extracranial cerebral vessels was negative. Cerebrospinal fluid examination (chloride 127 mmol/l, glucose 4.31 mmol/l, protein 0.33 g/l, lactate 1.70 mmol/l, and 1 leukocyte in 1 µl) was normal. There was positivity for paraneoplastic anti-SOX1 antibodies, and the patient's oncological screening (including a CT scan of his abdomen and chest) turned out negative.

Antibodies against *Campylobacter jejuni*, the herpes simplex virus, the cytomegalovirus, the *Epstein-Barr virus*, *Mycoplasma pneumoniae*, *Haemophilus influenzae*, *Chlamydia pneumoniae*, and *Borrelia burgdorferi* were negative.

EMG examination was within normal limits, except for a low SNAP (sensory nerve action potential) amplitude of the median nerve (0.57 uV) with adequate sural nerve amplitude (6.2 uV), which was a sign of sural sparing. H-reflex amplitude and latency in the right tibial nerve were 6.8 mV and 30.10 ms, respectively. In the right median nerve, H-reflex amplitude and latency were 0.9 mV and 25.60 ms, respectively.

VEP (visual evoked potentials) with prolonged N-P-N complexes may have been an indication of slight impairment in the visual pathway. Median nerve SSEP, BAEP, and MEP were within normal limits.

We did not find any cause for the combined internal and external ophthalmoplegia other than the prominent increase of anti-GQ1b level. We concluded that this was definitely one of the anti-GQ1b syndromes – “ophthalmoplegia without ataxia”. After 14 days of hospitalization, a gradual regression of the patient's external ophthalmoplegia became apparent, with latency prolongation. Moreover, there was regression of mydriasis. We did not find any evidence of a combination of isolated ophthalmoplegia and a generalized form of Guillain-Barre syndrome. Therefore, we did not administer immunotherapy. Four months later, the patient exhibited diplopia only on extreme left lateral gaze (he was unable to complete outward movement of the left eyeball), and his pupils were within normal limits. He returned to work and was allowed to drive.

## Discussion

The pathology of the pure form of FS is not clear. The primary electrophysiological finding in FS is an abnormality in sensory conduction [5]. Immunohistochemistry showed sequential pathological changes starting with IgG deposits at the nodes, complement activation, and formation of membrane attack complex at the nodal axolemma, disruption of nodal sodium channel clusters, lengthening of the nodal region, and detachment of the paranodal myelin terminal loops. Lengthening of the nodal region and detachment of paranodal terminal loops mimic paranodal demyelination; however, the pathology is on the axonal side [5]. In recent years, reversible conduction failure has been reported in patients with FS [4]. In FS, anti-GQ1b antibodies bind to axolemmal epitopes in the nodal region and to epitopes on myelin sheaths in the paranodal region. FS is a typical nodo-paranodopathy, and not a myelinopathy. Anti-GQ1b antibodies are highly enriched in the paranodal regions of the extramedullary portion of the oculomotor,

trochlear, and abducens nerves. In cases of internal ophthalmoplegia, anti-GQ1b antibody may be present in the ciliary ganglia [1]. In our patient, who was showing internal and external ophthalmoplegia without ataxia, serum antibodies against GQ1b increased by 413%. However, his cerebrospinal fluid findings were negative.

Diplopia is usually the first symptom of FS, followed by limb or gait ataxia within days. Additionally, there may be mild distal paresthesia, dysphagia, or mild proximal limb weakness in up to one half of cases [4]. External ophthalmoplegia is seen in all FS patients; on the other hand, internal ophthalmoplegia is observed only in a few cases of FS [3]. In patients with anti-GQ1b antibodies who exhibit ophthalmoplegia but no ataxia, there is a separate syndrome – ophthalmoplegia without ataxia. Among large clusters of Japanese patients with the anti-GQ1b antibody syndrome, internal ophthalmoplegia was present in 35% of patients with FS [4]. As for our patient, the earliest symptom, on the first day, included eye fatigue, followed by blurred vision on the second day, and diplopia with horizontal separation on the third day. Subsequently, he developed moderate ptosis, mydriasis. His only prevailing health problems were blurred vision with inability to read (including inability to read using only one eye), moderate ptosis, and diplopia.

Electrodiagnostic findings in FS are abnormal in most patients with absent or low-amplitude sensory nerve action potentials (SNAP) or sural sparing. [3]. H-reflex studies have shown absent responses with frequently normal SNAP amplitudes, suggesting selective involvement of Ia afferents. The pattern of sensory electrophysiology in Fisher syndrome is characterized by predominant involvement of Ia afferents of muscle spindles, with relatively preserved cutaneous afferents and without evidence suggestive of demyelination [6]. Our patient had normal H-reflexes (amplitude and latency) in the tibial and median nerves, which was consistent with preserved Ia muscle spindle afferents, and consequently, the absence of ataxia.

An analysis of sera of patients with Fisher syndrome for anti-GQ1b or anti-GT1a antibodies revealed that one half of these patients had the following antibodies: anti-GM1, anti-GD1a, and anti-GD1b. Based on antibody specificity, the FS-associated antibodies were subdivided into 3 types: GQ1b-specific, GM1/GQ1b-reactive, and GD1a/GQ1b-reactive [7]. “Anti-GQ1b syndrome” is a term used to describe some variants of Guillain-Barre syndrome with high levels of anti-GQ1b antibodies – Fisher syndrome, Bickerstaff brainstem encephalitis, acute ophthalmoplegia without ataxia, and ataxic polyneuropathy. FH/GBS overlap syndrome is characterized by Fisher syndrome (ophthalmoplegia, areflexia, and ataxia) and progressive tetraparesis with monophasic course. In addition to anti-GQ1b antibodies, anti-GT1a, anti-GM1b, anti-GD1g antibodies are present. Some patients with the overlap syndrome need artificial ventilation. In FH/GBS overlap syndrome, immunological therapy is indicated.

The differential diagnosis of acute ophthalmoplegia includes cerebrovascular diseases, aneurysms of the internal carotid artery, brainstem tumors, infections, diabetes mellitus, multiple sclerosis, and myasthenia gravis [1]. In individual cases, adequate investigation (neuroimaging, cerebrospinal fluid examination, and biochemical and hematological values) enables to rule out all of these causes. Ophthalmoplegia associated with ataxia and areflexia is not always FS. In fact, it can be caused by several pathological conditions. For the diagnosis of acute ophthalmoplegia without ataxia, the mandatory criteria include: an acute or subacute onset of external or internal ophthalmoplegia, the absence of other neurological symptoms, the

presence of anti-GQ1b IgG titers, and the exclusion of other identifiable causes [4]. In our patient, these criteria were fulfilled.

In patients presenting with acute or subacute onset of bilateral external ophthalmoplegia plus, possibly, internal ophthalmoplegia, and without ataxia, the anti-GQ1b antibody syndrome is the most probable cause.

## Acknowledgment

This work was supported by the grant MH CZ- DRO Faculty Hospital in Hradec Kralove (long-term organization development plan) (UHHK, 00179906) and by the grant PRVOUK: P37/08.

## References

1. Rigamonti A, Lauria G, Longoni M, Stanzani L, Agostoni E (2011) Acute isolated ophthalmoplegia with anti-GQ1b antibodies. *Neurol Sci* 32: 681-682.
2. Suzuki T, Chiba A, Kusunoki S, Chikuda M, Fujita T, et al. (1998) Anti-GQ1b ganglioside antibody and ophthalmoplegia of undetermined cause. *Br J Ophthalmol* 82: 916-918.
3. Piccione EA, Salame K, Katirji B (2014) Guillain-Barré syndrome and related disorders. *Neuromuscular disorders in clinical practice*. Springer: New York, USA
4. Ito M, Kuwabara S, Odaka M, Misawa S, Koga M, et al. (2008) Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. *J Neurol* 255: 674-682.
5. Uncini A, Kuwabara S (2012) Electrodiagnostic criteria for Guillain-Barré syndrome: a critical revision and the need for an update. *Clin Neurophysiol* 123: 1487-1495.
6. Sekiguchi Y, Misawa S, Shibuya K, Mitsuma S, Hirano S, et al. (2013) Patterns of sensory nerve conduction abnormalities in Fisher syndrome: more predominant involvement of group Ia afferents than skin afferents. *Clin Neurophysiol* 124: 1465-1469.
7. Kaida K, Kusunoki S (2010) Antibodies to gangliosides and ganglioside complexes in Guillain-Barré syndrome and Fisher syndrome: mini-review. *J Neuroimmunol* 223: 5-12.